Skip to main content

Table 2 General haemodynamics in animals subjected to acute pulmonary hypertension

From: Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension

Parameter Treatment Baseline Pulmonary hypertension
    Pre-inhalation 5 minutes after inhalation
HR (beats/minute) Iloprost 88 ± 12 112 ± 13* 109 ± 7*
  Control 90 ± 16 111 ± 14* 116 ± 15*
CO (l/minute) Iloprost 4.5 ± 0.5 5.0 ± 0.4 5.6 ± 0.9
  Control 4.1 ± 0.9 4.3 ± 0.6 3.9 ± 1.0
SV (ml) Iloprost 53 ± 6 45 ± 6 51 ± 9
  Control 45 ± 13 40 ± 10 35 ± 11
MAP (mmHg) Iloprost 86 ± 18 69 ± 16* 74 ± 17*
  Control 81 ± 7 70 ± 7* 70 ± 11*
LVEDP (mmHg) Iloprost 11 ± 2 10 ± 2 11 ± 2
  Control 11 ± 3 10 ± 3 11 ± 2
RVEDP (mmHg) Iloprost 10 ± 1 11 ± 1 10 ± 2
  Control 10 ± 2 12 ± 1 12 ± 1
SVR (dyn·s/cm5) Iloprost 1,329 ± 324 952 ± 337* 971 ± 406*
  Control 1,518 ± 344 1,087 ± 224* 1,257 ± 368*
PVR (dyn·s/cm5) Iloprost 178 ± 79 366 ± 126* 193 ± 66†‡
  Control 210 ± 105 448 ± 168* 464 ± 201*
PVR/SVR Iloprost 0.14 ± 0.06 0.39 ± 0.07* 0.21 ± 0.09
  Control 0.13 ± 0.05 0.41 ± 0.12* 0.37 ± 0.12*
  1. Values are shown for baseline and in pulmonary hypertension before inhalation and 5 minutes after inhalation of either iloprost or control. For the complete experimental time course, see Additional file 3. Values are expressed as mean ± standard deviation. *P < 0.05 versus baseline; P < 0.05 versus before inhalation; P < 0.05 iloprost versus control (corrected for multiple comparisons). CO, cardiac output; HR, heart rate; L(R)VEDP, left (right) ventricular end-diastolic pressure; MAP, mean arterial pressure; S(P)VR, systemic (pulmonary) vascular resistance; SV, stroke volume.